公开(公告)号：US20130030181A1

公开(公告)日：2013-01-31

申请号：US13644415

申请日：2012-10-04

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

IPC: C07D471/10

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。